Maxim Group reiterated their positive rating on shares of Radius Health, Inc. (NASDAQ:RDUS) in a research note published on Friday morning, The Fly reports. The analysts noted that the move was a valuation call.

RDUS has been the subject of several other reports. Cantor Fitzgerald set a $65.00 price objective on Radius Health and gave the stock a buy rating in a report on Sunday, June 4th. Canaccord Genuity set a $85.00 target price on Radius Health and gave the company a buy rating in a research note on Monday, July 31st. BidaskClub upgraded Radius Health from a hold rating to a buy rating in a research note on Tuesday, June 27th. Jefferies Group LLC reaffirmed a hold rating and issued a $38.00 target price (up from $34.00) on shares of Radius Health in a research report on Wednesday, August 9th. Finally, Zacks Investment Research raised Radius Health from a sell rating to a hold rating in a research report on Tuesday, August 8th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and five have given a buy rating to the stock. The company has a consensus rating of Hold and an average price target of $53.60.

Radius Health (NASDAQ:RDUS) opened at 38.55 on Friday. Radius Health has a 1-year low of $31.58 and a 1-year high of $55.97. The firm’s market capitalization is $1.68 billion. The stock has a 50 day moving average price of $36.80 and a 200 day moving average price of $38.96.

Radius Health (NASDAQ:RDUS) last issued its earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($1.58) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.35) by ($0.23). The business had revenue of $0.98 million for the quarter, compared to the consensus estimate of $1.96 million. During the same period in the prior year, the business earned ($1.01) earnings per share. Analysts predict that Radius Health will post ($5.58) EPS for the current year.

COPYRIGHT VIOLATION WARNING: This news story was originally published by Watch List News and is owned by of Watch List News. If you are accessing this news story on another publication, it was illegally stolen and reposted in violation of United States and international copyright & trademark law. The correct version of this news story can be viewed at https://www.watchlistnews.com/radius-healths-rdus-positive-rating-reiterated-at-maxim-group/1602400.html.

In other Radius Health news, major shareholder Growth N. V. Biotech bought 150,000 shares of the stock in a transaction on Thursday, August 10th. The shares were purchased at an average cost of $34.97 per share, with a total value of $5,245,500.00. Following the completion of the transaction, the insider now directly owns 5,113,799 shares of the company’s stock, valued at approximately $178,829,551.03. The purchase was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, major shareholder Growth N. V. Biotech bought 50,000 shares of the stock in a transaction on Tuesday, September 5th. The shares were acquired at an average cost of $36.75 per share, for a total transaction of $1,837,500.00. Following the completion of the transaction, the insider now directly owns 5,298,799 shares of the company’s stock, valued at $194,730,863.25. The disclosure for this purchase can be found here. In the last ninety days, insiders purchased 469,100 shares of company stock valued at $16,328,382. 15.00% of the stock is owned by company insiders.

Large investors have recently made changes to their positions in the business. State of Wisconsin Investment Board acquired a new stake in shares of Radius Health in the second quarter worth about $1,176,000. OppenheimerFunds Inc. increased its holdings in shares of Radius Health by 0.3% during the 1st quarter. OppenheimerFunds Inc. now owns 301,631 shares of the biopharmaceutical company’s stock valued at $11,658,000 after acquiring an additional 831 shares during the last quarter. American International Group Inc. increased its holdings in shares of Radius Health by 7.1% during the 1st quarter. American International Group Inc. now owns 19,430 shares of the biopharmaceutical company’s stock valued at $751,000 after acquiring an additional 1,284 shares during the last quarter. Trexquant Investment LP acquired a new position in shares of Radius Health during the 1st quarter valued at about $241,000. Finally, BlackRock Inc. increased its holdings in shares of Radius Health by 98,245.6% during the 1st quarter. BlackRock Inc. now owns 2,630,745 shares of the biopharmaceutical company’s stock valued at $101,679,000 after acquiring an additional 2,628,070 shares during the last quarter.

Radius Health Company Profile

Radius Health, Inc is a biopharmaceutical company. The Company is focused on the developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. The Company’s lead investigational product candidate, TYMLOS (abaloparatide-SC) injection is developed for the treatment of postmenopausal women with osteoporosis at high risk for fracture.

The Fly

Analyst Recommendations for Radius Health (NASDAQ:RDUS)

Receive News & Ratings for Radius Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.